ChemSpider 2D Image | GLPG0492 | C19H14F3N3O3

GLPG0492

  • Molecular FormulaC19H14F3N3O3
  • Average mass389.328 Da
  • Monoisotopic mass389.098724 Da
  • ChemSpider ID28661578

  • defined stereocentres - 1 of 1 defined stereocentres

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1215085-92-9 [RN]
4-[(4S)-4-(Hydroxymethyl)-3-methyl-2,5-dioxo-4-phenyl-1-imidazolidinyl]-2-(trifluormethyl)benzonitril [German] [ACD/IUPAC Name]
4-[(4S)-4-(Hydroxymethyl)-3-methyl-2,5-dioxo-4-phenyl-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile [ACD/IUPAC Name]
4-[(4S)-4-(Hydroxyméthyl)-3-méthyl-2,5-dioxo-4-phényl-1-imidazolidinyl]-2-(trifluorométhyl)benzonitrile [French] [ACD/IUPAC Name]
4-[(4S)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Benzonitrile, 4-[(4S)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenyl-1-imidazolidinyl]-2-(trifluoromethyl)- [ACD/Index Name]
GLPG0492
GLPG-0492
4-?[(4S)?-?4-?(hydroxymethyl)?-?3-?methyl-?2,?5-?dioxo-?4-?phenyl-?1-?imidazolidinyl]?-?2-?(trifluoromethyl)?-Benzonitrile
4-[(4S)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenyl-1-imidazolidinyl]-2-(trifluoromethyl)-benzonitrile
More...
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      Androgen Receptor MedChem Express HY-18102
      GLPG0492 is a novel selective androgen receptor modulator; exhibited anabolic activity on muscle, strongly dissociated from the androgenic activity on prostate after oral dosing. MedChem Express
      GLPG0492 is a novel selective androgen receptor modulator; exhibited anabolic activity on muscle, strongly dissociated from the androgenic activity on prostate after oral dosing.;IC50 value:;Target: AR modulatorGLPG0492 has very good pharmacokinetic properties, including bioavailability in rat (F > 50%), and is currently under evaluation in phase I clinical trials [1]. GLPG0492 is a new non-steroidal selective androgen receptor modulator that is currently under development for musculo-skeletal diseases such as sarcopenia and cachexia. In acute exhaustion tests, a surrogate of the 6-min walking test used in DMD patients, GLPG0492 preserved running performance, whereas vehicle- or comparator-treated animals showed a significant increase in fatigue (30-50%) [2]. GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP at reducing muscl MedChem Express HY-18102

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

Density: 1.5±0.1 g/cm3
Boiling Point: 544.0±60.0 °C at 760 mmHg
Vapour Pressure: 0.0±1.5 mmHg at 25°C
Enthalpy of Vaporization: 86.6±3.0 kJ/mol
Flash Point: 282.8±32.9 °C
Index of Refraction: 1.627
Molar Refractivity: 91.7±0.4 cm3
#H bond acceptors: 6
#H bond donors: 1
#Freely Rotating Bonds: 5
#Rule of 5 Violations: 0
ACD/LogP: 2.07
ACD/LogD (pH 5.5): 2.33
ACD/BCF (pH 5.5): 34.53
ACD/KOC (pH 5.5): 439.21
ACD/LogD (pH 7.4): 2.33
ACD/BCF (pH 7.4): 34.53
ACD/KOC (pH 7.4): 439.21
Polar Surface Area: 85 Å2
Polarizability: 36.3±0.5 10-24cm3
Surface Tension: 65.0±5.0 dyne/cm
Molar Volume: 258.6±5.0 cm3

Click to predict properties on the Chemicalize site


Advertisement